Recent Company News

• 08:05 PM ET May 18, 2026
  

  Innovent Biologics to present autoimmune/ophthalmology pipeline data at ATS and ARVO (HK$80.30, 0.00)

• 10:25 PM ET May 12, 2026
  

  Ascentage Pharma to present 17 clinical updates on olverembatinib and lisaftoclax at EHA 2026 (HK$41.52, -0.66)

• 08:06 PM ET May 10, 2026
  

  Innovent's IBI363 obtains third China breakthrough therapy designation for MSS/pMMR metastatic CRC (HK$90.00, 0.00)

• 01:09 PM ET May 08, 2026
  

  FDA grants orphan drug designation to IBI3003 for multiple myeloma (HK$90.00, 0.00)

• 09:36 PM ET May 05, 2026
  

  StreetAccount Sector Summary - China Healthcare April Recap

• 02:53 AM ET Apr 30, 2026
  

  Quick Take: Innovent Biologics +5.5% post Q1 update; driven by drug sales ramp-up post NRDL inclusion (HK$89.65, +4.75)

• 11:31 PM ET Apr 22, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 07:38 PM ET Apr 29, 2026
  

  Innovent Biologics provides Q1 update; product revenue over CNY3.8B, +50%+ y/y (HK$84.90, 0.00)

• 11:04 AM ET Apr 28, 2026
  

  Innovent Biologics releases sustainability report (HK$82.60, 0.00)